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INTRODUCTION
Mesenchymal stem cells (MSCs) are undifferentiated cells, de-
rived from bone marrow, and widely distributed in various tis-
sues of the body. MSCs can proliferate for many passages in cul-
ture and have the ability to give rise to several differentiated cell 
types under the influence of microenvironmental factors (1). These 
properties make them an attractive choice as a cell therapeutic 
agent (2-4). Growing evidences have shown that MSCs play an 
important role not only in regeneration and homeostasis, but 
also in the development and growth of human malignancies.
  Sasser et al. (5) investigated the direct biological impact of 
primary human bone marrow stromal cells on the growth rates 
of a panel of metastatic breast cancer cell lines, and then found 
that human bone marrow stromal cells enhanced breast cancer 
cell growth rates in a cell line-dependent manner when evaluat-
ed in 3D tumor environments. In contrast to these tumor-pro-
moting properties, Khakoo et al. (3) observed that intravenously 
Objectives. Mesenchymal stem cells (MSCs) play an important role in the development and growth of tumor cells. Howev-
er, the effect of human MSCs on the growth of human tumors is not well understood. The purpose of this study is to 
confirm the growth effect of palatine tonsil-derived MSCs (TD-MSCs) on head and neck squamous cell carcinoma 
(HNSCC) cell lines and to elucidate the mechanism of their action.
Methods. TD-MSCs were isolated from patient with chronic tonsillitis and tonsillar hypertrophy. Two human HNSCC cell 
lines (PNUH-12 and SNU-899) were studied and cocultured with isolated palatine tonsil-derived MSC. The growth 
inhibitory effect of MSCs on HNSCC cell lines was tested through methylthiazolyldiphenyl-tetrazolium (MTT) assay. 
The apoptosis induction effect of MSCs on cell lines was assessed with flow cytometry and reverse transcriptase (RT)-
PCR.
Results. Palatine tonsil-derived MSCs exhibited a growth inhibitory effect on both cell lines. Cell cycle analysis showed an 
accumulation of tumor cells predominantly in G0/G1 phase with an increase in concentration of TD-MSCs, which was 
confirmed by increased mRNA expression of cell cycle negative regulator p21. Apoptosis of tumor cells increased sig-
nificantly as concentration of cocultured TD-MSCs increased. Additionally, mRNA expression of caspase 3 was upre-
gulated with increased concentration of TD-MSCs.
Conclusion. TD-MSCs have a potential growth inhibitory effect on HNSCC cell lines in vitro by inducing apoptotic cell death 
and G1 phase arrest of cell lines.
Key Words. Apoptosis, Mesenchymal stem cells, Palatine tonsil, Squamous cell carcinoma 
  • Received April 24, 2011  
Revision December 25, 2011  
Accepted January 19, 2012 
  • Corresponding author: Byung-Joo Lee, MD 
Department of Otorhinolaryngology-Head and Neck Surgery, Pusan 
National University School of Medicine and Medical Research Institute, 
179 Gudeok-ro, Seo-gu, Busan 602-739, Korea  
Tel: +82-51-240-7335, Fax: +82-51-246-8668  
E-mail: voicelee@pusan.ac.krLim Y-S et al.: Anticancer Effect of Palatine Tonsil-derived Stem Cells    87
injected-human MSCs homed to sites of tumorigenesis and po-
tently inhibited tumor growth using an in vivo Kaposi’s sarcoma 
animal model.
  These findings means that the effect of MSCs on the tumor 
growth is not clear, and the inhibitory or promotive effect of 
MSCs on the tumor growth in vitro and in vivo is not well dem-
onstrated (5-8). In addition, there are few reports for growth ef-
fect of MSCs on head and neck squamous cell carcinoma (HN-
SCC) cell lines.
  Finding a suitable cell source of MSCs is a major challenge for 
cell therapy and tissue engineering. Although bone marrow (BM) 
has been the main source of MSCs (4, 9-15), the use of BM-de-
rived cells is not always acceptable due to the high degree of vi-
ral exposure, the possibility of donor morbidity, and the signifi-
cant decreases in cell number and proliferation/differentiation 
capacity with age (16). A highly invasive procedure is used to 
obtain BM, and, in this context, many efforts have been made to 
find an alternative MSC source in stem cell therapy. To date, MSCs 
have been isolated from a number of adult tissues, including tra-
becular bone (17), fat (18, 19), synovium (20, 21), skin (22), thy-
mus (23), periodontal ligament (24) as well as prenatal and peri-
natal tissues such as umbilical cord blood (25), umbilical cord 
(26), and placenta (27).
  Tonsils are easily accessible especially to otolaryngologist, par-
ticularly from young donors because of the prevalence of tonsil-
lectomy procedure, and, if necessary, tonsillar tissue can be easi-
ly obtained by biopsy without major complications under local 
anesthesia. Therefore, we noticed that the tonsil can be another 
source of MSCs. 
  We performed this study to observe the influence of tonsil de-
rived-mesenchymal stem cells (TD-MSCs) on growth of HNSCC 
and to elucidate the mechanism of the action further.
MATERIALS AND METHODS
Isolation and culture of tonsil stem cell
With institutional review board approval, tonsils were obtained 
after informed consent from patients undergoing tonsillectomy 
as a result of recurrent episodes of tonsillitis. To isolate tonsil 
stem cell, tonsil was washed extensively with equal volumes of 
phosphate-buffered saline (PBS), and tissue were digested at 
37°C for 30 minutes with 0.075% collagenase (type I; Sigma, 
St. Louis, MO, USA). Enzyme activity was neutralized with α- 
modified Eagle’s medium (α-MEM), containing 10% fetal bo-
vine serum (FBS) and centrifuged at 1,200 g for 10 minutes to 
obtain a pellet. The pellet was filtered through a 100-µm nylon 
mesh to remove cellular debris and incubated overnight at 37°C/ 
5% CO2 in control medium (α-MEM, 10% FBS, 100 unit/mL of 
penicillin, 100 µg/mL of streptomycin). Following incubation, 
the plate was washed extensively with PBS to remove residual 
nonadherent cells. The resulting cell population was maintained 
at 37°C/5% CO2 in control media. One-week later, when the 
mono  layer of adherent cells has reached confluence, cells were 
trypsinized (0.05% trysin-EDTA; Sigma) resuspended in α-MEM 
containing 10% FBS, and subcultured at a concentration of 
2,000 cells/cm
2.
Adipogenic, osteogenic, and chondrogenic differentiation of 
TD-MSCs
Adipogenic differentiation was induced by culturing tonsil stem 
cell for 2 weeks in adipogenic media (1 μM dexamethasone, 100 
µg/mL 3-isobutyl-1 methylxanthine, 5 µg/mL insulin, and 60 μM 
indomethacine, 10% FBS in α-MEM) and assessed using an oil 
red O (Sigma) stain as indicator of intracellular lipid accumula-
tion. Prior to staining, the cells were fixed 15 minutes at room 
temperature in 70% ethanol. The cells were incubated in 2% oil 
red O reagent for 1 hour at room temperature. Excess stain was 
removed by washing with 70% ethanol, followed by several 
changes of distilled water.
  Osteogenic differentiation was induced by culturing ADSC for 
2 weeks in osteogenic media (0.1 mM dexamethasone, 10 μM 
β-glycerophosphate, and 50 µg/mL ascorbic acid, 10% FBS in 
α-MEM) and examined for extracellular matrix calcification by 
alizarin red S (Sigma) staining. For alizarin red S staining, the 
cells fix with 70% ethanol and washed with distilled water. The 
cells were incubated in 2% arizarin red solution for 15 minutes 
at room temperature. The cells were washed several times with 
distilled water.
  For chondrogenic differentiation, cells were stimulated in chon-
drogenesis induction media for 3 weeks. Cells were then rinsed 
twice with PBS and fixed in 10% formalin for 15 minutes at 
room temperature. Alcian Blue (Sigma) was used to stain chon-
drogenic pellets. Excess dye was removed, and cells were visual-
ized by light microscopy.
Flow cytometry analysis
Flow cytometry analysis was used to characterize the pheno-
types of the ADSC. At least 50,000 cells (in 100 µL PBS/0.5% 
BSA/2 mmol/L EDTA) were incubated with FITC-labeled mono-
clonal antibodies against human CD73, CD90, CD105, CD45, 
CD31, CD117, HLA-DR (BD Biosciences Clontech, Palo Alto, 
CA, USA) or with the respective isotype control. After washing 
the labeled cells were analyzed by flow cytometry using FACS- 
Calibur flow cytometer and the CellQuest Pro software (BD Bio-
sciences).
Tumor cell lines
The laryngeal carcinoma cell line (SNU-899) was purchased from 
the Korean Cell Line Bank (28). PNUH-12 cells originating from 
hypopharyngeal squamous cell carcinoma were established at 
the Department of Otolaryngology, Pusan National University 
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Growth inhibition of tonsil stem cells on tumor cells
Human tonsil stem cells were isolated and treated with mitomy-
cin C (MMC) (50 µg/mL, Sigma) at 37°C for one hour to block 
the proliferation. Then cells were washed twice with PBS and 
plated 0.1 mL onto 96-well plates at different number of cells. 
Tumor cells were suspended in RPMI-1640 medium and added 
into wells with or without stem cells. The ratios of stem cells to 
tumor cells were 1:20, 1:10, 1:5, 1:2, and cells were cocultured 
for 48 hours. Then the culture was analyzed by methylthiazolyl-
diphenyl-tetrazolium (MTT) assay. 
  In MTT assay, MTT (0.5 mg/mL, pH 4.7; Sigma) was added 4 
hours before the end of the culture time. The supernatant was 
removed, 150 µL DMSO was added and shaken for 5 minutes 
at room temperature. The absorbance at 570 nm was measured 
with Microplate Spectrophotometer (Molecular Devices, Sunny-
vale, CA, USA). Inhibitory effect of stem cells on viability of tu-
mor cells was expressed as follows: inhibitory rate (%)=(OD570 
of tumor cells-OD570 of tumor with stem cells+OD570 of stem 
cells control)/OD570 of tumor cells×100%. The tumor cells orig-
inated from head and neck squamous cell carcinoma were co-
cultured with TD-MSCs at different cell number ratios for 48 
hours. In the time-dependent experiment, the ratio of TD-MSCs 
to tumor cells was 1:20. TD-MSCs and tumor cells were cocul-
tured for 24, 48, and 72 hours, respectively. The fibroblasts were 
purchased from the Korean Cell Line Bank (28) and treated by 
MMC at the same concentration. Then they were cocultured with 
tumor cells as the control group so that the influence of the por-
tion of MMC treated TD-MSCs mixed with tumor cells should 
be evaluated.
Analysis of cell cycle and apoptosis
To determine the effect of tonsil stem cells on cell death and cell 
cycle distribution of tumor cells, 5×10
4 stem cells were seeded 
onto 6-well plate and incubated for 18 hours. Then culture me-
dium was removed, the ratios of stem cells to tumor cells were 
1:20, 1:10, 1:5, 1:2 and cocultured for 48 hours. Cells were 
harvested, washed twice with PBS and measured by flow cyto-
metry analysis, reverse transcriptase (RT)-PCR, and real-time 
PCR assay. In flow cytometry analysis, 0.5 mL of PBS contain-
ing propidium iodide (5 mg/mL, BD Biosciences) was added to 
the culture before flow cytometry analysis (BD Biosciences). In 
RT-PCR analysis, total RNA was extracted from cucultured tu-
mor cells using TRIzol regent. RNA (1 µg) was reverse transcrib-
ed into cDNA using a PCR cDNA synthesis kit (Clontech Labo-
ratories Inc., Palo Alto, CA, USA). cDNA was used in the PCR 
normalized to β-actin gene. RNA (200 ng) was reverse transcrib-
ed and amplified using TaKaRa One-Step RT-PCR Kit (Takara 
Shuzo Co., Shiga, Japan). PCR was performed using the follow-
ing primers: p21 sense, (5´-CCCGAGAACGGT GGAACT -3´) 
and antisense (5´-AGAGGGCAGGCAGCGTAT-3´), product 
size: 493 bp; caspase 3 sense (5´-ATGTCATCTCGCTCTGGT 
-3´) and antisense (5´-TCTGTTTCTTTGCGTGGA-3´), product 
size: 604 bp; and β-actin sense (5´-GCCATGTACGTAGCCATC-
CA-3´) and antisense (5´-AACCGCTCATTGCCGATAGT-3´), 
product size: 373 bp. After 32 cycles of amplification, 10 μL of 
the reaction mix was removed, analyzed by 1.5% agarose gel 
electrophoresis and visualized by ethidium bromide staining.
  Real time PCR amplification of the cDNAs was carried out 
with the reverse-transecribed RNA, primers p21, product size: 
493 bp; caspase 3, product size: 604 bp; and β-actin, product 
size: 373 bp, using the Power SYBR Green PCR Master Mix 
(Applied Biosystems, Foster City, CA, USA). Reactions were 
run on a LightCycler detection system (Roche Molecular Sys-
tems, Alameda, CA, USA).
Statistical analysis
All experimental data were expressed as mean±SD of at least 
three independent experiments performed in duplicate. The sta-
tistical analysis was performed with the Student’s t-test or cova-
riance analysis for statistical significance. Statistical significance 
was set at a P-value of less than 0.05. All analyses were carried 
out using SPSS ver. 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Confirmation of multilineage differentiation of TD-MSC
To characterize the TD-MSC population, the isolated cells were 
analyzed using flow cytometry analysis. Cells were analyzed for 
the expression of cell membrane protein markers: positive for 
CD73, CD90, and CD105, which are generally considered as 
markers of MSCs, but negative for the expression of hematopoi-
etic markers such as CD45, CD31, and CD117 (Fig. 1A).
  TD-MSCs showed a fibroblast-like morphology and were plas-
tic adherent under standard culture conditions (Fig. 1B). The dif-
ferentiation potential for mesenchymal lineage was assessed by 
oil red O, alizarin red S, and alcian blue staining. TD-MSCs ex-
hibited a characteristic of differentiation morphology in induc-
tion medium but not control medium (Fig. 1B). Two weeks after 
adipogenic induction, morphology of lipid droplets were observ-
ed and stained by oil red O. Under osteogenic culture conditions 
after 3 weeks, calcium deposits were detected by alizarin red S 
staining. Chondrogenic differentiation was revealed by alcian 
blue staining after 3 weeks of chondrocyte induction (Fig. 1B).
Growth inhibition of TD-MSCs on tumor cells
TD-MSCs exhibited a number-dependent growth inhibitory ef-
fect on different tumor cell lines (Fig. 2), but not the time-depen-
dent effect (data not shown). However, fibroblast treated control 
showed neither a number-dependent nor the time-dependent 
growth inhibitory effect. In addition, TD-MSCs exhibited signifi-
cant growth inhibitory effect on each tumor cell line more than 
fibroblasts at the cell ratio of 1:5 or 1:2 (Fig. 2).Lim Y-S et al.: Anticancer Effect of Palatine Tonsil-derived Stem Cells    89
TD-MSCs induce cell cycle arrest of tumor cells in the G1 
phase
We characterized the effect of TD-MSCs on the cell cycle of tu-
mor cells to explain the mechanism of growth inhibition of MSCs. 
Cell cycle analysis showed an accumulation of tumor cells incre-
ased in G0/G1 phase with an increase in concentration of TD-
MSCs, which was statistically significant (PNUH-12, 33.1 vs. 
50.6; SNUH-899, 36.6% vs. 58.5%; P<0.05) on each tumor 
cell line (Fig. 3A, B). On the contrary, control showed the increas-
ed tumor cells in G0/G1 phase with an increase in concentration 
of TD-MSCs which was not statistically significant. Furthermore, 
the increase of G0/G1 phase was more in MSC treated SNU-899 
cell line than in fibroblast treated control at the cell ratio of 1:5 
and 1:2 (Fig. 3B). This phenomenon was confirmed by mRNA 
expression of cell cycle negative regulator p21. The results of RT- 
PCR demonstrated that TD-MSCs could upregulate mRNA ex-
pression of p21 in tumor cells significantly as concentration of 
TD-MSCs increased (Fig. 3C).
TD-MSCs induce the apoptosis of tumor cells
To address this issue, HNSCC cells were cocultured with TD-
MSCs, and tumor cells were harvested for apoptotic cell death 
and cell cycle distribution analysis. Apoptosis of tumor cells in-
creased significantly as concentration of cocultured TD-MSCs 
MSC expansion media Osteogenic Adipogenic Chondrogenic B
Fig. 1. Characterization and differentiation of tonsil derived-mesenchymal stem cells (TD-MSCs) analyzed by flow cytometry and microscopy. 
(A) The mesenchymal stem cell (MSC)-specific markers CD73, CD90, and CD105 were expressed in TD-MSCs, whereas the hematopoietic 
stem-cell markers CD45, CD31, and CD117 were not. (B) TD-MSCs showed a fibroblast-like morphology and had the ability for adipogenic, 
osteogenic, and chondrogenic differentiation in differentiation induction medium. Differentiated cells were stained with oil red O, alizarin red S, 
and alcian blue.
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Fig. 2. Tonsil derived-mesenchymal stem cells (TD-MSCs) shows methylthiazolyldiphenyl-tetrazolium (MTT) metabolism inhibitory effect on 
head and neck squamous cell carcinoma (HNSCC) tumor cells by number-dependent manner. 5×10
4 cells of each head and neck cancer 
cell line (PNUH-12 and SNU 899) were incubated with mitomycin C (MMC)-treated TD-MSC or fibroblast at different cell ratio (1:20, 1:10, 1:5, 
1:2), and cell viability was evaluated by the MTT assay (A) and (B). Results are mean inhibitory rate±SD of three independent experiments. 
*P<0.05 (compared with fibroblast treated control).
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Fig. 3. Tonsil derived-mesenchymal stem cells (TD-MSCs) induced 
cell cycle arrest of head and neck squamous cell carcinoma (HN-
SCC) tumor cells. 5×10
4 tumor cells were seeded onto 6-well 
plate and incubated for 18 hours. TD-MSCs and fibroblasts were 
cocultured for 48 hours at the cell ratio of 1:20, 1:10, 1:5, 1:2. 
Cells were harvested, washed twice with phosphate-buffered sa-
line and measured by flow cytometry analysis. An accumulation of 
tumor cells increased in G0/G1 phase with an increase in concen-
tration of TD-MSCs, which was statistically significant (PNUH-12, 
33.1% vs. 50.6%; SNUH-899, 36.6% vs. 58.5%; P<0.05) on each 
tumor cell line (A) and (B). The increa  se of G0/G1 phase in TD-
MSC treated SNU-899 cell line was more than in fibroblast treated 
control at the cell ratio of 1:5 and 1:2 (B). *P<0.05 (compared 
with fibroblast treated control).
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increased on each tumor cell line (Fig. 4), and TD-MSCs exhibit-
ed significantly increased apoptosis of tumor cells more than fi-
broblasts at the cell ratio of 1:10, 1:5, and 1:2. Additionally, 
upregulated mRNA expression of caspase 3 was demonstrated 
with increased concentration of TD-MSCs (Fig. 5). TD-MSCs 
treated PNUH-12 cell line exhibited significantly increased mRNA 
expression of caspase 3 more than fibroblast treated control at 
the cell ratio of 1:2 (Fig. 5B).
DISCUSSION
MSCs were first characterized by Friedenstein et al. (11, 12), who 
identified an adherent, fibroblast-like population from adult BM. 
Over the ensuing decades, BM-MSCs have been characterized 
and have proven to have the capacity to differentiate into sever-
al mesenchymal lineages under appropriate conditions (4, 9, 11, 
13). However, obtaining a BM sample requires some donor 
morbidities such as pain due to invasive procedure. These facts 
have led investigators to search for good substitutes for BM as 
an MSC source.
  The practical application of MSCs is limited by ethical and lo-
gistic problems related to their isolation and their potential im-
munogenicity because of the requirement for allogeneic trans-
plantation (2, 30-34). Ideal stem cells should be autologous cells 
that can be harvested without difficulty from the patient, ma-
nipulated efficiently in vitro, and implanted back into the same 
patient (32).
  In this study, we isolated and cultured MSCs from palatine 
tonsil tissues, and showed that these MSCs were positive for cell 
surface markers of typical MSCs. Usually tonsil-derived MSC is 
a particularly interesting alternative source of MSCs because 
Fig. 4. Cell cycle analysis shows apoptosis of tumor cells increased significantly as the cell ratio of cocultured tonsil derived-mesenchymal stem 
cells (TD-MSCs) increased on each tumor cell line (A) and (B). TD-MSCs exhibited significantly increased apoptosis of tumor cells more than 
fibroblasts at the cell ratio of 1:10, 1:5, and 1:2. *P<0.05, **P<0.001 (compared with fibroblast treated control).
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Fig. 5. Upregulated mRNA expression of caspase 3 is demonstrated with increased concentration of tonsil derived-mesenchymal stem cells 
(TD-MSCs) at each tumor cell line (A) and (B), which could support the apoptosis of tumor cells. *P<0.05 (compared with fibroblast treated 
control).
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tonsil can be obtained with a less invasive procedure. Tonsillar 
epithelium is derived from the second pharyngeal pouch (of en-
dodermal origin) and during fetal development is invaded by 
lymphoid tissue (of mesodermal origin). Therefore, embryologi-
cally, tonsils could be a source of MSCs. More importantly, the 
presence of MSCs in a secondary lymphoid organ underscores 
their potential contribution to a specialized microenvironment 
that supports the initiation and the maintenance of efficient im-
mune responses.
  Zhu et al. (8) reported that both fetal and adult BM could fa-
vor tumor growth in vitro (F6 or SW480) and in vivo. In mela-
noma murine tumor model, Djouad et al. (21) demonstrated the 
statistically higher incidence of tumor development in group in-
jected with B16 tumor cells and MSCs than in the control group 
injected with the B16 tumor cells alone.
  In contrast to these tumor-promoting properties, Lu et al. (35) 
investigated a number-dependent growth inhibitory effect of 
mouse BM-MSC on murine hepatoma and lymphoma cell lines 
and ascitogenous hepatoma cells in vivo without host immuno-
suppression. These finding could be explained by upregulated 
mRNA expression of cell cycle negative regulator p21 and apop-
tosis associated protease caspase 3 in tumor cells.
  In addition, there are differences of the effect of MSCs on the 
tumor growth between in vitro and in vivo (3, 7). Ramasamy et 
al. (7) reported that MSCs exhibited a similar antiproliferative 
activity on tumor cells of hematopoietic and non hematopoietic 
origin in vitro, but when tumor cells were injected into nonobese 
diabetic-severe combined immunodeficient mice in conjunction 
with MSCs, their growth was much faster as compared to the 
group receiving only tumor cells. For the discrepancy between 
the in vitro and in vivo behavior, they suggested that MSC have 
the ability to form a cancer stem cell niche in which tumor cells 
can preserve the potential to proliferate and sustain the malig-
nant process.
  In this experimental study, MSCs were isolated from human 
palatine tonsil. Their phenotypes were positive for CD73, CD90 
and negative for CD45. After cocultured with HNSCC cell lines, 
TD-MSCs exhibited growth inhibitory effect on tumor cell lines 
through decreased cell viability, which were explained by MTT 
assay. In addition, TD-MSCs exhibited a significant number-de-
pendent growth inhibitory effect on tumor cells through increas-
ed cell cycle arrest and apoptosis. These phenomenon were sup-
ported by G0/G1 cell cycle changes and expression of p21 and 
caspase 3.
  The current study demonstrate for the first time that TD-MSCs 
can induce potent growth inhibitory effect on HNSCC cell lines 
by increased cell cycle arrest and apoptosis. Their anticancer ac-
tivities and mechanism of action, especially in vivo, deserve to 
be investigated further. The therapeutic application of MSCs still 
remain limited unless the favorable effect of MSCs for tumor 
growth in vivo and the long-term safety of the clinical applica-
tions of MSCs are better understood.
  One of the limitations of this study is the possible influence of 
increasing portion of MMC treated TD-MSCs, which necessitate 
the application of MMC treated fibroblast for the control group. 
These factors originated from another limitation of the intermin-
gled growth pattern between TD-MSCs and tumor cells. Not-
withstanding these limitations, TD-MSCs showed the growth in-
hibitory effect on tumor cells that control group did not as the 
concentration of TD-MSCs and fibroblast increased. Moreover, 
TD-MSCs demonstrated the significantly increased growth inhi-
bition and apoptosis of tumor cells more than control.
  In conclusion, we isolated MSCs from human palatine tonsil 
successfully and demonstrated the growth inhibitory effect of 
TD-MSCs on HNSCC cell line by induction of cell cycle arrest 
and apoptosis.
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